CROSSJECT (FRA:74C) Other Stockholders Equity: €0.89 Mil (As of Dec. 2025)

CROSSJECT FRA:74C +0.26% 40 Other Stockholders Equity is €0.89 Mil as of Dec. 2025. GuruFocus rates FRA:74C with a GF Score™ of 40/100 and a GF Value™ of €1.16 (Significantly Overvalued). The stock has 4 warning signs investors should review.

CROSSJECT's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €0.89 Mil.

CROSSJECT's quarterly Other Stockholders Equity declined from Dec. 2024 (€0.97 Mil) to Jun. 2025 (€0.95 Mil) and declined from Jun. 2025 (€0.95 Mil) to Dec. 2025 (€0.89 Mil).

CROSSJECT's annual Other Stockholders Equity increased from Dec. 2023 (€0.67 Mil) to Dec. 2024 (€0.97 Mil) but then declined from Dec. 2024 (€0.97 Mil) to Dec. 2025 (€0.89 Mil).

CROSSJECT Other Stockholders Equity Related Terms

CROSSJECT Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for CROSSJECT's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CROSSJECT Other Stockholders Equity Chart

CROSSJECT Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Other Stockholders Equity

Get a 7-Day Free Trial

0.66

0.67

0.97

0.89

CROSSJECT Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Other Stockholders Equity	Get a 7-Day Free Trial															0.67	0.66	0.97	0.95	0.89

40GF Score

CROSSJECT FRA:74C

Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

CROSSJECT Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Frequently Asked Questions Learn more about Other Stockholders Equity →

What does a Other Stockholders Equity of €0.89 Mil mean?

CROSSJECT (FRA:74C) has a Other Stockholders Equity of €0.89 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on CROSSJECT and its competitors.

Is CROSSJECT's Other Stockholders Equity too high?

CROSSJECT's current Other Stockholders Equity is €0.89 Mil. Overall, CROSSJECT has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does CROSSJECT's Other Stockholders Equity compare to ISRG and BDX?

CROSSJECT's Other Stockholders Equity of €0.89 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Other Stockholders Equity for a Medical Devices & Instruments company?

A good Other Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Other Stockholders Equity mean?

A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on CROSSJECT and its competitors. CROSSJECT's current Other Stockholders Equity is €0.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is CROSSJECT stock overvalued right now?

Based on GuruFocus' analysis, CROSSJECT (FRA:74C) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.16, compared to a current price of €1.52 — trading 30.9% above its estimated fair value. The current Other Stockholders Equity is €0.89 Mil. CROSSJECT's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Other Stockholders Equity calculated?

Other Stockholders Equity is calculated from a company's financial statements. For CROSSJECT (FRA:74C), the current Other Stockholders Equity is €0.89 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CROSSJECT (FRA:74C) Overvalued in 2026?

Based on GuruFocus' analysis, CROSSJECT stock appears to be overvalued. The current stock price of €1.52 is trading 30.9% above its estimated GF Value™ of €1.16. GuruFocus considers CROSSJECT to be Significantly Overvalued.

Key valuation signals for FRA:74C:

Other Stockholders Equity: €0.89 Mil
GF Value™: €1.16 vs. price of €1.52 (30.9% above fair value)
GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the FRA:74C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.